Benzimidazole derivatives useful as CB-1 inverse agonists
申请人:Janssen Pharmaceutica NV
公开号:US10118900B2
公开(公告)日:2018-11-06
The present invention is directed to benzimidazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions mediated by the CB-1 receptor; more particularly, use in the treatment of disorders and conditions responsive to inverse agonism of the CB-1 receptor. More particularly, the compounds of the present invention are useful in the treatment of metabolic disorders.
ANTI-THROMBOTIC PEPTIDE AND PSEUDOPEPTIDE DERIVATIVES
申请人:RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC.
公开号:EP0584066A1
公开(公告)日:1994-03-02
TETRAHYDROISOQUINOLINE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS
申请人:SMITHKLINE BEECHAM PLC
公开号:EP0917530A1
公开(公告)日:1999-05-26
BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS
申请人:Janssen Pharmaceutica NV
公开号:US20170057929A1
公开(公告)日:2017-03-02
The present invention is directed to benzimidazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions mediated by the CB-1 receptor; more particularly, use in the treatment of disorders and conditions responsive to inverse agonism of the CB-1 receptor. More particularly, the compounds of the present invention are useful in the treatment of metabolic disorders.